Finecure Pharmaceuticals Limited IPO
Finecure Pharmaceuticals Limited IPO
Finecure Pharmaceuticals Limited was founded in 2005 with a mission and vision of “Making lives Healthier” by providing quality medicines with innovation and technology. Presently our company is leading manufacturers and marketers of Pharmaceutical formulations in several therapeutic segments in dosage forms of Tablets, Capsules, Oral Liquids, Dry Syrup, Powders, Injections, and Sachet.
Finecure has several accolades to its credit including
1. The Arch of Europe Award 2012,
2. Assocham India Business Excellence Award 2013,
3. Asia’s Most Promising Brand 2013-2014,
4. UBM – IPE Fastest Growing Pharma Company Award 2015 By Union Minister Dr. Harsh Vardhan,
5. MEDCON – Pharma Company of the Year 2016,
6. Brand Excellence award 2016 by ABP News healthcare leadership awards
7. Best Asian Healthcare Brands, 2017 Recognition for delivering Excellence in Healthcare at India UAE Conclave
8. Asia Pharma Excellence Award for pharma company of the Year 2017
9. CIMS Healthcare Excellence Award 2017 for Pharma Company of the Year in Penicillin.
10. Dream Companies to work for Pharmaceuticals 2017 World HRD Congress
The Company is poised for vertical growth, with modern facilities, skills and know-how and resources that are at par with the best in the country. The company has state-of-the-art manufacturing facilities and maintains all specific set of standards mandated by the Food and Drug Administration (FDA). The company is certified for WHO GMP, ISO 9001, ISO 22000, ISO 14001, OHSAS 18001 quality systems towards High Product Quality Assurance, Environment Management System, Occupational Health and safety. The company has received recognition from prestigious organizations like FICCI, ASSOCHAM, IDMA, and Pharmexcil acknowledging their excellence in the pharmaceutical market.
The Company is CRISIL 1A rated towards “Highest Performance Capability”. The company registered a compounded annual growth rate (CAGR) of 32.95 percent in revenue from 2012-13 to 2016-17 as against average industry CAGR between 12 to 14%.
Company Competitive Strength
1. Quality assurance and standards
2. Experienced management team
3. Diversified business operations and revenue base
4. Strong sales, marketing, and distribution capabilities
5. Enhanced focus on process development
6. Scalable Business Model
7. Global Presence
Objects of the Finecure Pharmaceuticals Limited IPO:
Finecure Pharmaceuticals Limited IPO
are: 1. The Offer for Sale 2. The Fresh Issue The Net Offer Proceeds are proposed to be utilized by our Company for the following objects: a) Purchasing capital equipment for our new manufacturing facility being set up at Sanand, Gujarat b) Funding the working capital requirement; c) General corporate purposes.Finecure Pharmaceuticals Limited IPO Details:
| Total Shares: | 43,40,000 |
| Face Value: | ₹ 10 Per Equity Share |
| Listing At: | NSE Emerge |
Promoters And Management:
Financials of Finecure Pharmaceuticals Limited IPO:
| Particulars | For the year/period ended (in Rs. Lacs) | ||||
| 30-Dec-2017 | 31-Mar-17 | 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | |
| Total Assets | 4,275.06 | 3,539.20 | 2,346.40 | 1,948.97 | 1,099.42 |
| Total Revenue | 8,477.71 | 9,840.87 | 8,828.35 | 6,573.23 | 4,583.90 |
| Profit After Tax | 1,081.74 | 1,371.02 | 1,085.42 | 719.71 | 443.15 |
Recommendation on Finecure Pharmaceuticals Limited IPO:
Finecure Pharmaceuticals Limited IPO
from our side is: Under Analysis. We'll update it soon here.Lead Manager of Finecure Pharmaceuticals Limited IPO:
Registrar of Finecure Pharmaceuticals Limited IPO:
Company Address:
Discussion on Finecure Pharmaceuticals Limited IPO:
Leave a Reply
You must be logged in to post a comment.